ABBV
AbbVie
$230.01
▲ 6.2%Updated Today 7:15 PM ET
▲ Up 16.7% over the last 12 months
Market Cap
$382.49B
P/E
104.35x
Forward P/E (est.)
120.6x
ROE
95.6%
Revenue Growth
9.5%
EPS Growth
-13.5%
Profit Margin
5.8%
FCF Yield
3.9%
Debt / Equity
20.19x
ROIC
21.0%
Interest Coverage
5.21x
Current Ratio
0.8x
Dividend Yield
3.1%
Implied Growth (rev. DCF)
4.1%
Rating Score
31/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ABBV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ABBV trades near $230.01, above its 50-day average ($211.77) and 200-day average ($220.57). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 49 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. ABBV's is $5.68 (~2.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ABBV found buyers near $208.99 (support) and sellers near $230.47 (resistance); its 52-week range is $181.73–$244.81. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.8× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
AbbVie (ABBV) is a mega-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $382.49B.
In its latest reported year it generated about $61.16B in revenue and $4.23B in net profit.
Our model rates ABBV Weak (31/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
2.1%
Revenue moved from $56.20B in 2021 to $61.16B in 2025, a 2.1% compound annual growth rate. The most recent year grew a steady 9.5% year over year. Slower, mature growth is common for established businesses.
Gross Margin
72.0%
Operating Margin
24.6%
Net Margin
6.9%
ROE
95.6%
AbbVie keeps about 5.8% of each sales dollar as net profit, with a 72.0% gross margin and 24.6% operating margin. Return on equity is 95.6% and return on invested capital about 21.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$64.50B
Net Debt
$55.11B
Net Debt / EBITDA
3.66x
Debt / Equity
20.19x
Leverage: debt-to-equity is 20.2x, and operating profit covers interest about 5.2x, with a current ratio of 0.8x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $64.50B of total debt against $9.39B of cash.
Operating CF
$19.03B
Free Cash Flow
$17.82B
FCF Margin
29.1%
In the latest year AbbVie produced about $19.03B of operating cash flow and $17.82B of free cash flow after capital spending. That is a free-cash-flow yield of about 3.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
104.35x
P/S
6.37x
P/B
91.9x
EV / EBITDA
—
ABBV trades at 104.4x trailing earnings (about 120.6x on estimated forward earnings), 6.4x sales, and 91.9x book value. Reverse-engineering today's price implies the market expects roughly 4.1% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How ABBV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), ABBV ranks #54 of 59 by our overall rating. It trades at a premium versus the sector on earnings (104.4x P/E vs. 25.4x median) with a higher return on equity (95.6% vs. 14.9%) and faster revenue growth (9.5% vs. 7.9%).
P/E vs sector
104.4x
median 25.4x
ROE vs sector
95.6%
median 14.9%
Growth vs sector
9.5%
median 7.9%
Sector rank
#54
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$241.96 – $405.86
vs. $230.01 today · expected CAGR 1% – 12%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $67.28B | $74.00B | $81.40B | $89.54B | $98.50B |
| Net income | $4.71B | $5.18B | $5.70B | $6.27B | $6.89B |
| EPS | $2.67 | $2.93 | $3.23 | $3.55 | $3.90 |
| Share price (low) | $165.26 | $181.78 | $199.96 | $219.96 | $241.96 |
| Share price (high) | $277.21 | $304.93 | $335.42 | $368.96 | $405.86 |
| CAGR (low–high) | -28% / 21% | -11% / 15% | -5% / 13% | -1% / 13% | 1% / 12% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ABBV:
- Strong return on equity (95.6%) shows capital is put to work well.
- Pays a 3.1% dividend on top of any price gains.
The case against ABBV:
- Elevated leverage (debt/equity 20.2x) adds financial risk.
- A rich 104.4x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (31/100).
Valuation risk — at 104.4x earnings, disappointing results could compress the multiple.
Balance-sheet risk — debt/equity of 20.2x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: AbbVie is a mega-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 104.4x earnings, which our model scores Weak (31/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.